Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Ani Pharmaceuticals (ANIP) over the last 11 years, with Sep 2025 value amounting to $5.2 million.

  • Ani Pharmaceuticals' Gains from Investment Securities was N/A to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year change of. This contributed to the annual value of $5.3 million for FY2024, which is 13.40% up from last year.
  • Ani Pharmaceuticals' Gains from Investment Securities amounted to $5.2 million in Q3 2025, which was down 1.93% from $5.3 million recorded in Q1 2024.
  • Ani Pharmaceuticals' 5-year Gains from Investment Securities high stood at $5.3 million for Q1 2024, and its period low was -$1.1 million during Q2 2022.
  • In the last 3 years, Ani Pharmaceuticals' Gains from Investment Securities had a median value of $4.9 million in 2023 and averaged $3.8 million.
  • Data for Ani Pharmaceuticals' Gains from Investment Securities shows a peak YoY soared of 510.87% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Ani Pharmaceuticals' Gains from Investment Securities stood at $2.5 million in 2022, then skyrocketed by 510.87% to $216,000 in 2023, then reached $5.3 million in 2024, then reached $5.2 million in 2025.
  • Its Gains from Investment Securities stands at $5.2 million for Q3 2025, versus $5.3 million for Q1 2024 and $216,000 for Q4 2023.